Avadel Pharmaceuticals plc ADR buy BiotechBee
Zusammenfassung
Diese Einschätzung wird gerade geschlossen. Mit einer Rendite von 11,03 % entwickelt sich die Einschätzung BUY im Moment ganz nach Plan. BiotechBee hat 70% Zuversicht bei dieser EinschätzungAvadel Pharmaceuticals: A Brief Overview
Avadel Pharmaceuticals (Symbol: FLML, WKN A2DJR8) is a specialty pharmaceutical company publicly traded on the stock exchange, which focuses on the development, manufacturing, and commercialization of innovative pharmaceutical products. By utilizing their proprietary drug delivery technology platform, Avadel aims to improve the performance and patient experience of existing drugs, primarily within the areas of central nervous system (CNS) disorders and sleep medicine. Headquartered in Dublin, Ireland, this company combines both research and development expertise along with strong commercial capabilities to bring unique solutions for patients in need. One of their prominent products, FT218, is an investigational once-nightly sodium oxybate formulation for the treatment of narcolepsy - an example of their dedication to revolutionizing sleep medicine.
Rendite ohne Dividenden (%)
| Name | 1W | 1M | 1J |
|---|---|---|---|
| Avadel Pharmaceuticals plc ADR | - | - | - |
| iShares Core DAX® | 0,73 % | 1,46 % | 17,98 % |
| iShares Nasdaq 100 | -2,69 % | -0,15 % | 3,81 % |
| iShares Nikkei 225® | -2,26 % | -2,73 % | 11,68 % |
| iShares S&P 500 | -1,35 % | 0,47 % | 1,97 % |
Was spricht laut BiotechBee für und gegen Avadel Pharmaceuticals plc ADR in den nächsten Jahren?
Pro
Kontra
Kommentare von BiotechBee zu dieser Einschätzung
In der Diskussion Avadel Pharmaceuticals plc ADR diskutieren